Lee Sang Yang, Kawasaki Keikichi, Inagaki Katsunori
Department of Orthopaedic Surgery, Showa University School of Medicine, 1-5-8 Hatano-dai, Shinagawa-ku, Tokyo, Japan.
Department of Orthopaedic Surgery, Keijinkai Shiroyama Hospital, 1 Iizuka-cho, Ota, Japan.
Trauma Case Rep. 2021 Dec 23;37:100595. doi: 10.1016/j.tcr.2021.100595. eCollection 2022 Feb.
Romosozumab is a humanized monoclonal anti-sclerostin antibody (Scl-Ab) that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. In 2019, the Japanese Ministry of Health, Labor and Welfare, and the FDA approved romosozumab for treating osteoporosis in men and in postmenopausal women at high risk of fracture. In the past decade, pharmacological systemic treatments using molecules in use for the treatment of the osteoporosis have been reported. Herein we reported the case of a 67-year-old woman with nonunion of humerus shaft fracture, in whom bone union could not be achieved after 11 months of conservative treatment; however, successful bone healing was achieved after once-a-month administration of romosozumab for 6 months. To our knowledge, this is the first case reporting the successful use of romosozumab for treating established nonunion. Romosozumab can aid in promoting bone healing of nonunion in patients not willing to undergo surgical intervention.
罗莫单抗是一种人源化抗硬化蛋白单克隆抗体（Scl-Ab），它能结合并抑制硬化蛋白，从而增加骨形成并减少骨吸收。2019年，日本厚生劳动省和美国食品药品监督管理局批准罗莫单抗用于治疗男性和有高骨折风险的绝经后女性的骨质疏松症。在过去十年中，已经报道了使用用于治疗骨质疏松症的分子进行的全身性药物治疗。在此，我们报告了一名67岁肱骨干骨折不愈合的女性病例，该患者在保守治疗11个月后仍未实现骨愈合；然而，在每月一次注射罗莫单抗6个月后成功实现了骨愈合。据我们所知，这是首例报道成功使用罗莫单抗治疗已形成的骨折不愈合的病例。罗莫单抗有助于促进不愿接受手术干预的患者骨折不愈合处的骨愈合。
